Evidence map›Paper›PMID 40221501›Full record

ArticleScientific reports2025

Comprehensive bioinformatics and immunohistochemical analyses identify phosphoinositide metabolism and PNPLA7 as potential biomarkers in urological cancers.

Yinhao Chen, Mingde Gao, Peng Chen, Amit Sharma, Maria Fitria Setiawan, Maria A Gonzalez-Carmona, Xiaolin Wang, Ingo G H Schmidt-Wolf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yinhao Chen *Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Mingde Gao *Department of Urology, Affiliated Tumor Hospital of Nantong University and Nantong Tumor Hospital, No. 30, Tongyang North Road, Tongzhou District, Nantong, 226361, Jiangsu, People's Republic of China.
Peng Chen *Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Amit SharmaDepartment of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Maria Fitria SetiawanDepartment of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital of Bonn, Venusberg Campus 1, 53127, Bonn, Germany.
Maria A Gonzalez-CarmonaDepartment of Internal Medicine I, University Hospital Bonn, Bonn, Germany.
Xiaolin WangDepartment of Urology, Affiliated Tumor Hospital of Nantong University and Nantong Tumor Hospital, No. 30, Tongyang North Road, Tongzhou District, Nantong, 226361, Jiangsu, People's Republic of China. cxhwyc2010@163.com.
Ingo G H Schmidt-WolfDepartment of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital of Bonn, Venusberg Campus 1, 53127, Bonn, Germany. ingo.schmidt-wolf@ukbonn.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Phosphoinositides (PI) and their metabolic enzymes are known to be involved in cellular processes associated with the hallmarks of cancer. The impact of PI metabolism-related components on urinary tract (or urological) cancers, however, remains unexplored. Considering this, herein, we performed a comprehensive bioinformatic analysis on clear cell renal carcinoma, bladder cancer, and adenocarcinoma of the prostate using public databases to investigate the relative contribution of PI metabolism in these clinical phenotypes. Primarily, we computed phosphoinositide metabolism scores to assess the associated biological processes and further enriched the analysis by predicting drug sensitivity, immune profiling, and risk stratification. Besides, we utilized single-cell RNA sequencing datasets to identify intercellular communication networks associated with PI metabolism in these cancer subtypes. Of interest, our analysis identified the PNPLA7 gene as a potential biomarker in urological cancers, which we validated using immunohistochemical evaluation of clinical samples. In conclusion, our study reveals that PI metabolism is a critical prognostic biomarker for urological cancers and may guide drug therapies, including immunosuppressants. Therefore, PNPLA7 could serve as a potential target and requires further attention.

Indexed as

Biomarkers, TumorComputational BiologyMonoacylglycerol LipasesPhosphatidylinositolsUrologic NeoplasmsGene Expression Regulation, NeoplasticHumansImmunohistochemistryMalePrognosisBiomarkers, TumorMonoacylglycerol LipasesPhosphatidylinositolsBioinformaticsMachine learningPhosphoinositide metabolismRisk stratificationUrological cancers

Identifiers

PMID40221501
PMCPMC11993629

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.